medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

The 2020 U.S. cancer screening deficit and the timing of adults' most recent screen: A population-based quasi-experiment

Jason Semprini[1,2] **and Radhika Ranganthan**[3]

[1]University of Iowa, College of Public Health; [2]University of Iowa, Department of Health Management Policy; [3]University of South Carolina, School of Public Health

***For correspondence:** jason-semprini@uiowa.edu

[†]The authors have no conflict of interests to disclose
[‡]This work received no funding
[§]Preliminary work for this study was presented at 10th Annual Symposium on Global Cancer Research (National Cancer Institute)

Present address: [§]145 N. Riverside Dr. N265, Iowa City, IA United States

Abstract In 2020, cancer screenings declined, then rebounded, resulting in a cancer screening deficit. The significance of this deficit, however, has yet to be quantified from a population health perspective. Our study addresses this evidence gap by examining how the pandemic changed the timing of American adults' most recent cancer screen. We obtained population-based, cancer screening data from the Behavioral Risk Factor Surveillance System. Mammograms, pap smears, and colonoscopies were each specified as a variable of mutually exclusive categories to indicate the timing since the most recent screening (never, 0-1 years, 1-2 years, 3+ years). Our quasi-experimental design restricts the sample to adults surveyed in January, February, or March. We then leverage a quirk in the BRFSS implementation and consider adults surveyed in the second year of each survey wave as the quasi-treatment cohort. Next, we constructed Linear and Logistic regression models which control for exogenous sociodemographic characteristics, state fixed effects, and temporal trends. Our results suggest that the deficit in 2020 was largely due to a one year delay among adults who receive annual screening, as the proportion of adults reporting a cancer screen in the past year declined by a nearly identical proportion of adults reporting their most recent cancer screen 1-2 years ago (3% to 4% points). However, the relative change was higher for mammograms and pap smears (17%) than colonoscopies (4%). We also found some evidence that the proportion of women reporting never having completed a mammogram declined in 2020, but the mechanisms for this finding should be further explored with the release of future data. Our estimates for the pandemic's effect on cancer screening rates are smaller than prior studies, but because we account for temporal trends we believe prior studies overestimated the effect of the pandemic and underestimated the overall downward trend in cancer screenings across the country leading up to 2020.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Background

Despite the critical importance of early cancer detection, cancer screening rates in America are well below public policy targets, rife with racial and socioeconomic disparities, and despite considerable resources, stagnating (Suran 2022; Sabatino et al. 2022; Benavidez et al. 2021). Then came 2020, the first year of the COVID-19 Pandemic.

Even before the first wave of the COVID-19 Pandemic, predictions for cancer prevention and control systems were dire. Given the elevated risk to cancer patients, either from adverse COVID-19 outcomes or consequences of delayed cancer treatment, health systems needed to adapt to ensure the safety of cancer patients during these initial months of the pandemic (Al-Quteimat and Amer 2020; Anderson et al. 2020; Matos et al. 2021). These risk mitigation and continuity of care policies may have prevented dramatic declines in the proportion of cancer patients receiving care (Davidson et al. 2022; Semprini 2022). Unfortunately, cancer screening was less of a priority during the early months of the public health emergency (DeJong, Katz, and Covinsky 2021).

Cancer screening could have been impacted by a number of federal, state, or local public health emergency policies, as well as by the changing priorities and capacities of health systems, and by individual social distancing behaviors (Cancino et al. 2020; Richards et al. 2020; DeJong, Katz, and Covinsky 2021). More recent research illuminated the role of financial stress and time costs as individual-level barriers to cancer screening, both of which may have compounded the strain on health systems attempting to resume cancer screening programs (Hanna et al. 2022; Peoples et al. 2022; Findling, Blendon, and Benson 2020).

There has been no shortage of evidence highlighting the stark decline in cancer screening services during the initial stages of the pandemic. Evidence from hospital records or insurance claims have suggested that, compared to pre-pandemic levels, mammograms, pap smears and colonoscopies declined 60% to 90% in March/April 2020 (Duszak et al. 2020; Bakouny et al. 2021; Staib, Catlett, and DaCosta Byfield 2021. However, subsequent research has found that in the later months of 2020, claims and records of cancer screenings returned to pre-pandemic levels (Chen et al. 2021); DeGroff et al. 2021; Labaki et al. 2021; McBain et al. 2021; Bello, Chang, and Massarweh 2022; Drescher et al. 2022). Still, the pandemic created a major cancer screening deficit which may be difficult to address despite recent investment in "return to screening" initiatives (Chen et al. 2021; Hanna et al. 2022; Kelkar et al. 2022). Even as America returns to screening, some are being left behind (Mafi et al. 2022. In fact, among the adults reporting having delayed cancer screenings during the 2020 pandemic year only 25% have plans to return to screening (Suran 2022).

New Contributions

Clearly, the COVID-19 pandemic created a cancer screening deficit in 2020. However, our understanding of this deficit is limited to hospital and claims based data, which is not necessarily a valid representation of the population's screening behavior. Moreover, the limited population-based

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

research has attempted to quantify changing patterns in cancer screening by comparing rates in 2020 with 2019, or an average of prior years, essentially assuming that any change observed in 2020 was due to the pandemic (Fedewa et al. 2022; Dennis, Hsu, and Arrington 2021; Richardson 2022). This assumption, however, may not be valid as several factors could impact temporal screening patterns (Semprini 2022). Finally, few studies have attempted to infer the significance of this decline or deficit in cancer screenings in terms of how the time since the most recent cancer screen may have changed (Fedewa et al. 2022). This is critical for "return to screening" initiatives, as targeting or prioritizing health system capacity should consider the pandemic's effect on the timing of a cancer screen; not just for adults who delayed care for a year, but for adults who delayed for longer or even delayed initiating their first cancer screen.

Our study addresses these evidence gaps by designing a population-based quasi-experimental Event History Analysis, where we compare the year-by-year change in the timing of the most recent cancer screen among adults not exposed to the 2020 pandemic with the change in adults exposed to a full year of the pandemic. This approach allows us to control for temporal trends in screening patterns and rigorously assess the internal validity of our design.

Results

Event-History Estimates (Linear Model)

In short, we find evidence that in 2020, exposure to the COVID-19 pandemic was associated with changing patterns of self-reported cancer screenings. Our estimates reveal that for the quasi-treatment cohort (late survey wave) in 2020, reports of a cancer screen in the past year declined as reports of a most recent cancer in the past 1-2 years increased. In 2020 for the quasi-treatment cohort, we also estimate a significant decline in self-reports of never having had a mammogram, which corresponds to a 33% relative decline from baseline rates of women reporting never having completed a mammogram. The absolute change for reporting a most recent mammogram in the past 1-2 years increased 4.2% points, which corresponds to a 17.5% increase from pre-pandemic rates of having reported a recent mammogram in 1-2 years. Similarly, the absolute change for reporting a most recent pap smear in the past 1-2 years increased 4.2% points, representing a 17.3% relative increase from pre-pandemic rates. Finally, reports of a colonoscopy in the past year were estimated to have declined by 3.5% points, a 4.3% relative change from baseline.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Year-by-Year Differences in Screening Rates for Late Survey Cohort

		2010*Late		**2012*Late**		**2014*Late**		**2016*Late**		**2020*Late**		***2020 Relative Change***
Mammogram	Never	-0.006	(0.018)	0.009	(0.016)	-0.013	(0.014)	-0.017	(0.012)	-0.029*	(0.013)	-33.0%
	<1 Year	-0.011	(0.023)	-0.030	(0.024)	0.004	(0.023)	0.020	(0.021)	-0.021	(0.034)	-3.5%
	1-2 Years	-0.008	(0.020)	0.003	(0.018)	0.002	(0.020)	-0.000	(0.016)	0.031*	(0.015)	17.5%
	3+ Years	0.025	(0.021)	0.018	(0.018)	0.007	(0.012)	-0.002	(0.015)	0.020	(0.024)	11.5%
Pap Smear	Never	0.017	(0.010)	-0.011	(0.014)	-0.024*	(0.009)	-0.009	(0.010)	-0.011	(0.012)	*-22.2%*
	<1 Year	0.019	(0.023)	0.015	(0.025)	0.046*	(0.020)	-0.007	(0.015)	-0.043	(0.031)	*-13.5%*
	1-2 Years	-0.008	(0.015)	-0.014	(0.017)	0.003	(0.017)	0.024	(0.014)	0.042*	(0.019)	*17.3%*
	3+ Years	-0.028	(0.015)	0.010	(0.019)	-0.026	(0.017)	-0.008	(0.017)	0.012	(0.018)	*10.2%*
Colonoscopy	Never	0.025	(0.017)	0.045*	(0.021)	0.042	(0.029)	-0.011	(0.022)	-0.010	(0.020)	*-1.06*
	<1 Year	-0.032	(0.022)	-0.012	(0.017)	-0.031	(0.030)	0.013	(0.018)	-0.035*	(0.016)	*-4.3%*
	1-2 Years	0.016	(0.031)	-0.035	(0.020)	0.011	(0.025)	-0.009	(0.019)	0.030	(0.016)	*3.8%*
	3+ Years	-0.009	(0.020)	0.002	(0.012)	-0.023	(0.019)	0.008	(0.018)	0.015	(0.019)	*2.1%*

*Table 1 reports the year-by-year differences in cancer screening rates between the early and late survey cohorts. All analyses control for exogenous sociodemographic characteristics, state-level fixed effects, and temporal trends (year fixed effects). Robust standard errors were clustered at the state level and reported in parentheses. The relative change was estimated by computing the semi-elasticity (relative marginal effect) of belonging to the late survey cohort in 2020. * $p < 0.05$.*

Marginal Effect Estimates (Logistic Model)

Figures 1-3 visually report the non-linear, average marginal effect estimates (derived from the results of the multinomial logistic model). Here, for each screening type and category, the average marginal effect of belonging to the quasi-treatment cohort for each year of the analysis. For our 2020 year of interest, we estimate average marginal effects significantly different than zero for mammograms in the past 1-2 years, pap smears in the past 1-2 years, and colonoscopies in the past year. However, we also see years when the average marginal effect of belonging to the quasi-treatment cohort was significantly different than zero in pre-pandemic years.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1: Marginal Effect of Late Survey Group on Rates of Most Recent Mammogram



Figure 1 shows the marginal effect estimates for each category of the most recent self-reported mammograms for the late-survey wave cohort. These estimates were based on the results of the multinomial logistic model and were averaged across all observations.

Figure 2: Marginal Effect of Late Survey Group on Rates of Most Recent Pap Smear



Figure 2 shows the marginal effect estimates for each category of the most recent self-reported pap smears for the late-survey wave cohort. These estimates were based on the results of the multinomial logistic model and were averaged across all observations.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3: Marginal Effect of Late Survey Group on Rates of Most Recent Colon/Sigmoidoscopy



Figure 3 shows the marginal effect estimates for each category of the most recent self-reported colonoscopies for the late-survey wave cohort. These estimates were based on the results of the multinomial logistic model and were averaged across all observations.

Sensitivity Checks

Our effect estimates and inference do not appear sensitive to linear or non-linear model specification. Supplemental table 2 shows the 2020*Late effect estimates for the linear probability model specification and the multinomial logistic model specification. For each type of screening and screening category, none of the estimates are significantly different from each other. Further, our inference (whether to reject the null hypothesis that screening rates were similar in 2020 for the late survey cohort) changed. The major takeaway from Table 2 in the supplemental file is that the effect estimates in the non-linear model were more precise (smaller standard errors) for significant estimates for mammograms and colonoscopies.

Now while the estimates do not change with regard to including state-fixed effects, clustering robust standard errors, and weighting our analyses, our inference would change depending on the preferred specification. In the supplemental file, table 3 shows the alternative designs (Alt 1 - no state fixed effects, Alt 2 - no state fixed effects, no clustering robust standard errors, Alt 3 - no state fixed effects, no clustering robust standard errors, and no probability sampling weights). For each of the three alternative specifications, the effect estimates for having never reported a mammogram in 2020 lose their significance. Moreover, for effect estimates of mammograms in the past year and past 1-2 years, inference appears to change across alternative specifications. Inference for the effect estimates on pap smears and colonoscopies also, slightly, varies across alternative specifications. However, more interest were the increased number of significant pre-trend test

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

statistics when excluding state fixed effects for both types of screenings. We suggest that this finding warrants inclusion the of the state-fixed effects to account for differential, time-invariant screening rates between quasi-treatment cohorts. Moreover, failing to account for clustering and weighting within each state may also add noise to our inference. Compared to our primary specification, our sensitivity analyses result in more differential pre-trend tests where we reject the null hypothesis (of no differential trends). Thus, we conclude that our primary specification is the most internally valid design.

Assessing internal validity

Comparability of quasi-treatment cohorts

Upon observing the unadjusted reports of a most recent cancer screen prior to 2020, we find little convincing evidence to believe that screening rates in the two groups differed before the first pandemic year. Supplemental Figures 2-4 visually depict the unadjusted cancer screening rates for our quasi-treatment (late survey wave) and quasi-control (early survey wave), for each year in our analyses. For each category of mammograms and pap smears, we see nearly identical trends and levels in the most recent screening from 2010-2018. For adults reporting never having completed a colonoscopy and adults reporting a colonscopy in the past year, we do see some possible non-common levels from 2010-14, but the trends and levels appear similar from 2016-2018.

The results of our two-sample proportion tests further validate our assumption, that these two quasi-treatment cohorts had simliar baseline screening rates. Note that Table 4 in the supplemental files does report a few screening outcomes with p-values under 0.05, but these test statistics are not significantly different than zero after accounting for multiple hypothesis testing (significance threshold $p < 0.0125$). Further, we fail to reject the null hypothesis that the sample composition of these two quasi-treatment groups are significantly different from each other (Table 5 in supplemental files).

Differential Trend Tests

We found evidence that screening rates in 2020 were significantly different between the two quasi-treatment cohorts. To infer a causal effect, however, we rely on the assumption that, in the absence of the pandemic, the change in screening rates would not have been observed for the late-survey wave cohort. To test the validity of this assumption, we empirically tested for differential trends prior to 2020. In the supplemental file, table 6 reports the year-by-year effect estimates (absolute differences) between quasi-treatment cohorts after excluding year 2020 from the analysis. We find no statistically significant differences in these effect estimates for mammograms. Moreover, the joint test of significance for each mammogram category exceeds the threshold to reject the null hypothesis that 2010, 2012, 2014, and 2016 coefficients equal zero (note, multiple hypothesis testing threshold set at $p < 0.0125$).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We do however, detect the potential for differential trends in pap smears, specifically for adults reporting never having completed a pap smear and having completed a pap smear in the past year. The source of the potential pre-trend differences are observed in 2014. For both categories, we reject the null hypothesis that pap smear screening trends were similar prior to 2020 ($p < 0.0125$).

Additionally, we detect the presence of differential trends for adults reporting their most recent colon/sigmoidoscopy three or more years prior. Again, the source of the differential pre-trend is observed in 2014. We reject the null hypothesis that, prior to 2020, reports of a colon/sigmoidoscopy three or more years ago were similar between the two quasi-treatment groups ($p < 0.0125$).

Discussion/Conclusion

The dire predictions and early evidence that cancer screening dramatically declined prompted investment and capacity for "return to screening" initiatives and patient prioritization policies (Joung et al. 2022; Sprague et al. 2021). However, most early predictions focused on the initial decline, as opposed to the subsequent rebound, and so did most of the early research. Even the research which accounted for the rebound, failed to account for other, non-pandemic factors which could be biasing the cancer screening deficit estimate. Our study does not claim that the pandemic had no impact on cancer screening rates over the course of 2020. We found higher proportions of women completing their most recent mammogram and pap smear 1-2 years ago. We also found lower proportion of adults completing their colonoscopy in the past year. However, our point estimates are smaller than the most recent population-based research (Fedewa et al. 2022). We attribute this difference to the fact that our study includes adults exposed, not just to the entire pandemic year, but to the "rebound period". Additionally, our Event-History design attempts to control for temporal changes which could be affecting cancer screening rates in ways unrelated to the pandemic, which other studies may fail to identify with simple pre/post designs. The implications of our findings suggest that "return to screening" initiatives and prioritization policies based on the overestimated effects of the pandemic on screening, may fail to achieve greater screening adherence. This is especially true for adults who have been delaying recommended cancer screenings for three or more years, delays which started before the pandemic year. To advance cancer equity, future research must continue monitoring the post-2020 cancer screening rebound to assess who is still delaying cancer screenings and how effective programs are mitigating these long-term delays. Finally, our results not only signal delayed cancer screening in 2020, but increased initiation. The proportion of women reporting to have never completed a mammogram declined for our late cohort in 2020 (relative to the change in the early cohort). Did the "return to screening" policies navigate new patients to their first mammogram? Or, was this decline merely a result of a "lower population denominator" after a year of elevated excess mortality? Future data can help us understand the mechanisms influencing the post-COVID screening rebound, which will be critical for advancing efforts to improve early cancer detection in America well beyond this pandemic.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Methods and Materials

Data

We analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS), a cross-sectional random-digit-dialed, telephonic survey (both landline and cellphone) of nationally representative sample involving non-institutionalized civilian population, aged 18 years or older, who reside in the United States (CDC 2021). This population based self-reported, ongoing survey is conducted across all 50 states, DC and three US territories, which collects information on behavioral health risks, chronic conditions and the usage of preventive services covering more than 400,000 adult interviews each wave year.

Sample

Our study population included non-institutionalized adults 18 years or older, residing in the US (including DC), interviewed between January 1st to March 31st, for the even years (2010 – 2020). Based on BRFSS cancer module eligibility, we included adults who were asked whether or not they have received a mammogram, pap smear and/or sigmoidoscopy/colonoscopy screening services (CDC 2021). We then restricted our analysis to adults eligible for each respective cancer screen based on the United States Preventative Task Force: Mammograms (females age 40-74; Pap Smears (females age 25-64); and Colon/sigmoidoscopies (males and females age 45-79) (Moyer et al. 2012; Siu et al. 2016; Davidson et al. 2021). Participants from unknown US territories/jurisdictions, those who were interviewed between April 1st to December 31st for the years 2010 to 2020, those interviewed in the years which did not utilize cancer modules (odd years), were all excluded (Supplemental Figure 1).

Analytical Design

From the perspective of the analyst, the ideal experiment to evaluate how the COVID-19 pandemic impacted cancer screening would be to randomly assign adults into two groups: those exposed and those not exposed to the pandemic. After tracking individual screening behavior over time, any difference observed during the pandemic year (2020) would be attributed to the COVID-19 pandemic. This design is comically unrealistic. Unfortunately, quasi-experimental designs using "as-if" randomization into treatment and controls are also infeasible. Because the COVID-19 pandemic was a global event, everyone was exposed and everyone was impacted. Simple pre/post analyses have attempted to measure the change in cancer screening rates, but these approaches fail to account for other temporal factors which could be influencing screening rates in ways unrelated to the pandemic.

Rather than attempt to create different groups based on exposure to the pandemic during the pandemic year, we take a different approach by leveraging how BRFSS implements its cross-sectional survey over the course of 15 months. Selection into the BRFSS sample is random. When

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

adults are surveyed, is also random. Therefore there is no reason to expect any observable differences in cancer screening behavior between adults queried early in a single year BRFSS survey wave and adults queried later in that same BRFSS survey wave; except however, during the COVID-19 pandemic year.

Our design begins by creating two distinct quasi-cohorts of adult BRFSS respondents. The first cohort only includes adults surveyed between January 1 and March 31 of the first year in each survey wave. We consider this "early" cohort the control group. Our second cohort only includes adults surveyed between January 1 and March 31 of the second year in each survey wave. We consider this "late" cohort the treatment group. Tables 2 (in the supplemental file) reports the cancer screening rates for both quasi-treatment and control cohorts for years 2010-2018. We test for significant differences in proportions between both groups and report the t-statistic and respective p-value to assess the comparability of these groups prior to 2020. We also conduct similar proportion tests for the sample composition of our control variables.

Prior to 2020, we hypothesize that screening behavior is not significantly different between our control and treatment groups. We also hypothesize that, prior to 2020, the trends in screening behavior do not differentially vary by group (see statistical analysis section below for details on these identification tests). Evidence that levels and trends did not vary between groups prior to 2020 supports our identification assumption: that any difference in screening rates observed in 2020 should be attributed to the COVID-19 pandemic.

Statistical Analysis For each of the three cancer screenings (mammograms, pap smears, and colonoscopies), we model the probability of self-reported cancer screening behavior as mutually exclusive categories related to the timing of the most recent screen. This approach not only allows us to model the change in probabilities over time, but also model how the distribution of cancer screening behavior changes between each timing category. Our initial specification models the probability of a recent cancer screen as a series of linear probability models.

$$1)\ Y^m_{its} = P(Y^m = y | X_i, t = YEAR, s = STATE)$$

Where Y^m_{its} is a binary variable indicating if the respondent reported a cancer screening in time interval m. X_i is a vector of control variables potentially impacting cancer screening rates, but exogenous to the COVID-19 pandemic. This set of exogenous dummy variables includes age (five-year age groups), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic other), education status (no highschool, high school degree only or GED, some college but no four-year degree, four-year college degree only or at least some graduate-level education and/or degree), whether the respondent is married, and whether the respondent is male. To account for secular trends in cancer screening, each model includes YEAR, a vector of binary fixed-effects variables indicating the survey wave year. These survey wave fixed effects account for temporal trends

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

in cancer screening. Finally, to account for time-invariant, regional behaviors, policies, and health systems impacting cancer screening, each model includes s, a vector of binary fixed-effects variables indicating the state of residence for each respondent.

We then estimate the incremental effect of the COVID-19 pandemic on screening behavior Y^m_{its} as:

$$2)\ \Delta SCREENING^m = \frac{\Delta Y^m_{its}}{\Delta PANDEMIC} = \frac{\Delta Y^m_{its}}{\Delta(2020|treatment)}$$

Where the estimated effect equals a change in Y^m_{its} given an incremental change in pandemic status (modeled as the incremental change of a dummy variable indicating if the year is 2020, for adults in the treatment group). Rather than implement a simple pre/post design, we explicitly allow the screening behavior in the treatment group to vary from the screening behavior in the control group for each year of the analysis (Clarke and Tapia-Schythe 2021). The event history study model is defined as:

$$3)\ Y^m_{its} = \beta * YEAR'_t * TREATED_i + YEAR'_t + X'_I + STATE'_S + e_{its}$$

B identifies the average association between cancer screening behavior Y^m for adults surveyed in the later part of each BRFSS survey wave. Using 2019 as the arbitrary baseline category, our event history analysis yields five B parameters (2010*Late, 2012*Late, 2014*Late, 2016*Late, and 2020*Late) This approach also allows us to test if $\Delta Y^m_{its} = \Delta PANDEMIC = (2020|control) = 0$ (Borusyak, Jaravel, and Spiess 2022). More importantly, we can now visually assess and empirically test our identification assumptions (Marcus and SantAnna 2021). Following best practice, we formally conduct pre-treatment differential trend tests by excluding responses in the 2020 survey wave and then recompute equation 3 (Freyaldenhoven, Hansen, and Shapiro 2019). In addition to reporting for each YEAR*TREATED coefficient, we calculate robust Wald statistics (with Bonferonni correction) to test if the trends in cancer screening rates between quasi-treatment and control cohorts jointly equalled zero (Armstrong 2014). Any significant results from these pre-treatment tests would suggest that cancer screening behaviors were differentially changing for treatment, compared to control cohorts, in ways unrelated to the COVID-19 pandemic. Conversely, null results provide confidence in the strength of our identifying assumption and supports the validity of our study design.

All analyses incorporate BRFSS supplied sampling weights, estimate standard errors robust to heteroskedasticity, and cluster the robust standard errors at the state level (Abadie et al. 2017; Cameron and Miller 2015). The Bonferonni correction method was used to adjust for multiple hypothesis testing for group differences and pre-treatment joint Wald tests (Armstrong 2014.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Alternative Specifications

Because of its ability to consistently model time-trends and group (i.e., state) fixed effects, the linear probability model is typically the preferred specification in the quasi-experimental literature. However, analytical issues may arise if the linear predictions are estimating potential outcomes outside the bounds of zero and one. In the presence of these nonsensical predictions, the linear probability model may be yielding biased estimates. To confront this threat, we construct an alternative set of specifications and model the probability of a recent cancer diagnosis with a multinomial logistic regression model. After comparing the predicted probabilities of these nonlinear models with the predictions of our linear model, we use the coefficients in the nonlinear models to estimate the average incremental effect of the treatment group (compared to the control group) in each year on the probability of each cancer outcome (Williams 2012). We also extend this marginal analysis to estimate the semi-elasticity, or relative change from baseline screening rates, for the treatment group in 2020 (Williams 2012). To support our inference, we test if the point estimates and standard errors in our linear models are significantly different from the estimates in the nonlinear specifications. A final set of sensitivity analyses relax the model assumptions by 1) removing the state-specific fixed effects, 2) remove state-specific fixed effects and estimate (unclustered) robust standard errors, 3) remove state-fixed effects, estimate (unclustered) robust standard errors, and ignore probability sampling weights.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

Abadie, Alberto, Susan Athey, Guido W. Imbens, and Jeffrey Wooldridge. *When Should You Adjust Standard Errors for Clustering?* Working Paper 24003. Series: Working Paper Series. National Bureau of Economic Research, November 2017. Accessed June 2, 2022. https://doi.org/10.3386/w24003. https://www.nber.org/papers/w24003.

Anderson, Roy M., Hans Heesterbeek, Don Klinkenberg, and T. Déirdre Hollingsworth. "How will country-based mitigation measures influence the course of the COVID-19 epidemic?" Publisher: Elsevier, *The Lancet* 395, no. 10228 (March 21, 2020): 931–934. ISSN: 0140-6736, 1474-547X, accessed April 3, 2020. https://doi.org/10.1016/S0140-6736(20)30567-5. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30567-5/abstract.

Armstrong, RA. "When to use the Bonferroni correction." *Ophthalmic Physiol Opt*, April 2014. Accessed June 2, 2022. https://doi.org/10.1111/opo.12131. https://pubmed.ncbi.nlm.nih.gov/24697967/.

Bakouny, Ziad, Marco Paciotti, Andrew L. Schmidt, Stuart R. Lipsitz, Toni K. Choueiri, and Quoc-Dien Trinh. "Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic." *JAMA Oncology* 7, no. 3 (March 1, 2021): 458–460. ISSN: 2374-2437, accessed November 18, 2021. https://doi.org/10.1001/jamaoncol.2020.7600. https://doi.org/10.1001/jamaoncol.2020.7600.

Bello, Ricardo J., George J. Chang, and Nader N. Massarweh. "Colorectal Cancer Screening in the USStill Putting the Cart Before the Horse?" *JAMA Oncology*, May 5, 2022. ISSN: 2374-2437, accessed June 2, 2022. https://doi.org/10.1001/jamaoncol.2022.0500. https://doi.org/10.1001/jamaoncol.2022.0500.

Benavidez, Gabriel A., Anja Zgodic, Whitney E. Zahnd, and Jan M. Eberth. "Disparities in Meeting USPSTF Breast, Cervical, and Colorectal Cancer Screening Guidelines Among Women in the United States." *Preventing Chronic Disease* 18 (April 15, 2021): E37. ISSN: 1545-1151, accessed March 2, 2022. https://doi.org/10.5888/pcd18.200315. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051853/.

Bitler, Marianne P., Christopher S. Carpenter, and Danea Horn. "Effects of the Colorectal Cancer Control Program." _Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/hec.4397, *Health Economics* 30, no. 11 (2021): 2667–2685. ISSN: 1099-1050, accessed June 2, 2022. https://doi.org/10.1002/hec.4397. https://onlinelibrary.wiley.com/doi/abs/10.1002/hec.4397.

Borusyak, Kirill, Xavier Jaravel, and Jann Spiess. *Revisiting Event Study Designs: Robust and Efficient Estimation*. SSRN Scholarly Paper 2826228. Rochester, NY: Social Science Research Network, April 19, 2022. Accessed June 2, 2022. https://doi.org/10.2139/ssrn.2826228. https://papers.ssrn.com/abstract=2826228.

Cameron, A. Colin, and Douglas L. Miller. "A Practitioners Guide to Cluster-Robust Inference." Publisher: University of Wisconsin Press, *Journal of Human Resources* 50, no. 2 (March 31, 2015): 317–372. ISSN: 0022-166X, 1548-8004, accessed June 2, 2022. https://doi.org/10.3368/jhr.50.2.317. http://jhr.uwpress.org/content/50/2/317.

Cancino, Ramon S., Zhaohui Su, Ruben Mesa, Gail E. Tomlinson, and Jing Wang. "The Impact of COVID-19 on Cancer Screening: Challenges and Opportunities." Company: JMIR Cancer Distributor: JMIR Cancer Institution: JMIR Cancer Label: JMIR Cancer Publisher: JMIR Publications Inc., Toronto, Canada, *JMIR Cancer* 6, no. 2 (October 29, 2020): e21697. Accessed June 2, 2022. https://doi.org/10.2196/21697. https://cancer.jmir.org/2020/2/e21697.

CDC. "Behavioral Risk Factor Surveillance System [2010-2020]," 2021. Accessed January 2, 2022. https://www.cdc.gov/brfss/annual_data/annual_2020.html.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Chen, Ronald C., Kevin Haynes, Simo Du, John Barron, and Aaron J. Katz. "Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic." *JAMA Oncology* 7, no. 6 (June 1, 2021): 878–884. ISSN: 2374-2437, accessed March 11, 2022. https://doi.org/10.1001/jamaoncol.2021.0884. https://doi.org/10.1001/jamaoncol.2021.0884.

Clarke, Damian, and Kathya Tapia-Schythe. "Implementing the panel event study." Publisher: SAGE Publications, *The Stata Journal* 21, no. 4 (December 1, 2021): 853–884. ISSN: 1536-867X, accessed June 2, 2022. https://doi.org/10.1177/1536867X211063144. https://doi.org/10.1177/1536867X211063144.

Davidson, Karina W., Michael J. Barry, Carol M. Mangione, Michael Cabana, Aaron B. Caughey, Esa M. Davis, Katrina E. Donahue, et al. "Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement." *JAMA* 325, no. 19 (May 18, 2021): 1965–1977. ISSN: 1538-3598. https://doi.org/10.1001/jama.2021.6238.

Davidson, Nancy E., Karen E. Knudsen, Shelley Fuld Nasso, Randall Oyer, Steve Pergam, Lara Strawbridge, and Lawrence Shulman. "Cancer Care at the Beginning of the COVID-19 Pandemic: Effects on Patients and Early Interventions to Mitigate Stresses on Care." *The Cancer Journal* 28, no. 2 (April 2022): 107–110. ISSN: 1528-9117, accessed June 2, 2022. https://doi.org/10.1097/PPO.0000000000000586. https://journals.lww.com/journalppo/Fulltext/2022/03000/Cancer_Care_at_the_Beginning_of_the_COVID_19.5.aspx.

DeGroff, A., J. Miller, K. Sharma, J. Sun, W. Helsel, W. Kammerer, T. Rockwell, et al. "COVID-19 impact on screening test volume through the National Breast and Cervical Cancer early detection program, JanuaryJune 2020, in the United States." *Preventive Medicine*, From disruption to recovery: The Impact of the COVID-19 Pandemic on Cancer Screening, 151 (October 1, 2021): 106559. ISSN: 0091-7435, accessed June 2, 2022. https://doi.org/10.1016/j.ypmed.2021.106559. https://www.sciencedirect.com/science/article/pii/S0091743521001432.

DeJong, Colette, Mitchell H. Katz, and Kenneth Covinsky. "Deferral of Care for Serious NonCOVID-19 Conditions: A Hidden Harm of COVID-19." *JAMA Internal Medicine* 181, no. 2 (February 1, 2021): 274. ISSN: 2168-6106, accessed April 5, 2022. https://doi.org/10.1001/jamainternmed.2020.4016. https://doi.org/10.1001/jamainternmed.2020.4016.

Dennis, Leslie K., Chiu-Hsieh Hsu, and Amanda K. Arrington. "Reduction in Standard Cancer Screening in 2020 throughout the U.S." Number: 23 Publisher: Multidisciplinary Digital Publishing Institute, *Cancers* 13, no. 23 (January 2021): 5918. ISSN: 2072-6694, accessed June 2, 2022. https://doi.org/10.3390/cancers13235918. https://www.mdpi.com/2072-6694/13/23/5918.

Drescher, Charles W., Adam J. Bograd, Shu-Ching Chang, Roshanthi K. Weerasinghe, Ann Vita, and R. Bryan Bell. "Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up." _Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34067, *Cancer* 128, no. 7 (2022): 1475–1482. ISSN: 1097-0142, accessed June 2, 2022. https://doi.org/10.1002/cncr.34067. https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34067.

Duszak, Richard, Jeff Maze, Candice Sessa, Howard B. Fleishon, Lauren P. Golding, Gregory N. Nicola, and Danny R. Hughes. "Characteristics of COVID-19 Community Practice Declines in Noninvasive Diagnostic Imaging Professional Work." Publisher: Elsevier, *Journal of the American College of Radiology* 17, no. 11 (November 1, 2020): 1453–1459. ISSN: 1546-1440, 1558-349X, accessed June 2, 2022. https://doi.org/10.1016/j.jacr.2020.06.031. https://www.jacr.org/article/S1546-1440(20)30742-0/fulltext.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Fedewa, Stacey A., Jessica Star, Priti Bandi, Adair Minihan, Xuesong Han, K. Robin Yabroff, and Ahmedin Jemal. "Changes in Cancer Screening in the US During the COVID-19 Pandemic." *JAMA Network Open* 5, no. 6 (June 2022): e2215490–e2215490. ISSN: 2574-3805. https://doi.org/10.1001/jamanetworkopen.2022.15490. eprint: https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2792956/fedewa_2022_oi_220453_1653581780.1564.pdf. https://doi.org/10.1001/jamanetworkopen.2022.15490.

Fedewa, Stacey A., K. Robin Yabroff, Priti Bandi, Robert A. Smith, Nigar Nargis, Zhiyuan Zheng, Jeffrey Drope, and Ahmedin Jemal. "Unemployment and cancer screening: Baseline estimates to inform health care delivery in the context of COVID-19 economic distress." *Cancer* 128, no. 4 (February 15, 2022): 737–745. ISSN: 1097-0142. https://doi.org/10.1002/cncr.33966.

Findling, Mary G., Robert J. Blendon, and John M. Benson. "Delayed Care with Harmful Health Consequences-Reported Experiences from National Surveys During Coronavirus Disease 2019." *JAMA Health Forum* 1, no. 12 (December 14, 2020): e201463. ISSN: 2689-0186, accessed March 11, 2022. https://doi.org/10.1001/jamahealthforum.2020.1463. https://doi.org/10.1001/jamahealthforum.2020.1463.

Freyaldenhoven, Simon, Christian Hansen, and Jesse M. Shapiro. "Pre-event Trends in the Panel Event-Study Design." *American Economic Review* 109, no. 9 (September 2019): 3307–3338. ISSN: 0002-8282, accessed June 2, 2022. https://doi.org/10.1257/aer.20180609. https://www.aeaweb.org/articles?id=10.1257/aer.20180609.

Hanna, Karim, Brandy L. Arredondo, Melody N. Chavez, Carley Geiss, Emma Hume, Laura Szalacha, Shannon M. Christy, et al. "Cancer Screening Among Rural and Urban Clinics During COVID-19: A Multistate Qualitative Study." Publisher: Wolters Kluwer, *JCO Oncology Practice*, March 7, 2022, OP.21.00658. ISSN: 2688-1527, accessed March 29, 2022. https://doi.org/10.1200/OP.21.00658. https://ascopubs.org/doi/full/10.1200/OP.21.00658.

Joung, Rachel H., Heidi Nelson, Timothy W. Mullett, Scott H. Kurtzman, Sarah Shafir, James B. Harris, Katharine A. Yao, Brian C. Brajcich, Karl Y. Bilimoria, and William G. Cance. "A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic." _Eprint: https://onlinelibrary.wiley.com *Cancer* 128, no. 11 (2022): 2119–2125. ISSN: 1097-0142, accessed June 2, 2022. https://doi.org/10.1002/cncr.34157. https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34157.

Kelkar, Amar H., Jing Zhao, Shu Wang, and Christopher R. Cogle. "Impact of the COVID-19 Pandemic on Colorectal and Prostate Cancer Screening in a Large U.S. Health System." Number: 2 Publisher: Multidisciplinary Digital Publishing Institute, *Healthcare* 10, no. 2 (February 2022): 264. ISSN: 2227-9032, accessed June 2, 2022. https://doi.org/10.3390/healthcare10020264. https://www.mdpi.com/2227-9032/10/2/264.

Labaki, Chris, Ziad Bakouny, Andrew Schmidt, Stuart R. Lipsitz, Timothy R. Rebbeck, Quoc-Dien Trinh, and Toni K. Choueiri. "Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic." *Cancer Cell* 39, no. 8 (August 9, 2021): 1042–1044. ISSN: 1535-6108, accessed June 2, 2022. https://doi.org/10.1016/j.ccell.2021.06.019. https://www.sciencedirect.com/science/article/pii/S153561082100341X.

Mafi, John N., Melody Craff, Sitaram Vangala, Thomas Pu, Dale Skinner, Cyrus Tabatabai-Yazdi, Anikia Nelson, et al. "Trends in US Ambulatory Care Patterns During the COVID-19 Pandemic, 2019-2021." *JAMA* 327, no. 3 (January 18, 2022): 237–247. ISSN: 0098-7484, accessed June 2, 2022. https://doi.org/10.1001/jama.2021.24294. https://doi.org/10.1001/jama.2021.24294.

Marcus, Michelle, and Pedro H. C. SantAnna. "The Role of Parallel Trends in Event Study Settings: An Application to Environmental Economics." Publisher: The University of Chicago Press, *Journal of the Association of Environmental and Resource Economists* 8, no. 2 (March 2021): 235–275. ISSN: 2333-5955, accessed June 2, 2022. https://doi.org/10.1086/711509. https://www.journals.uchicago.edu/doi/full/10.1086/711509.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Matos, Leandro L., Carlos Henrique Q. Forster, Gustavo N. Marta, Gilberto Castro Junior, John A. Ridge, Daisy Hirata, Adalberto Miranda-Filho, et al. "The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model." *Cancer causes & control: CCC* 32, no. 5 (May 2021): 459–471. ISSN: 1573-7225. https://doi.org/10.1007/s10552-021-01411-7.

McBain, Ryan K., Jonathan H. Cantor, Anupam B. Jena, Megan F. Pera, Dena M. Bravata, and Christopher M. Whaley. "Decline and Rebound in Routine Cancer Screening Rates During the COVID-19 Pandemic." *Journal of General Internal Medicine* 36, no. 6 (June 1, 2021): 1829–1831. ISSN: 1525-1497, accessed June 2, 2022. https://doi.org/10.1007/s11606-021-06660-5. https://doi.org/10.1007/s11606-021-06660-5.

Moyer, Virginia A., and U.S. Preventive Services Task Force. "Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement." *Annals of Internal Medicine* 156, no. 12 (June 19, 2012): 880–891, W312. ISSN: 1539-3704. https://doi.org/10.7326/0003-4819-156-12-201206190-00424.

Peoples, Anita R., Laura B. Oswald, Jennifer Ose, Bailee Daniels, Caroline Himbert, Cassandra A. Hathaway, Biljana Gigic, et al. "Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions." _Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/jrh.12648, *The Journal of Rural Health* n/a (n/a 2022). ISSN: 1748-0361, accessed March 29, 2022. https://doi.org/10.1111/jrh.12648. https://onlinelibrary.wiley.com/doi/abs/10.1111/jrh.12648.

Al-Quteimat, Osama M., and Amer Mustafa Amer. "The Impact of the COVID-19 Pandemic on Cancer Patients." *American Journal of Clinical Oncology* 43, no. 6 (June 2020): 452–455. ISSN: 0277-3732, accessed November 18, 2021. https://doi.org/10.1097/COC.0000000000000712. https://journals.lww.com/amjclinicaloncology/fulltext/2020/06000/the_impact_of_the_covid_19_pandemic_on_cancer.12.aspx.

Richards, Mike, Michael Anderson, Paul Carter, Benjamin L. Ebert, and Elias Mossialos. "The impact of the COVID-19 pandemic on cancer care." Number: 6 Publisher: Nature Publishing Group, *Nature Cancer* 1, no. 6 (June 2020): 565–567. ISSN: 2662-1347, accessed April 6, 2022. https://doi.org/10.1038/s43018-020-0074-y. https://www.nature.com/articles/s43018-020-0074-y.

Richardson, Lisa C. "Adults Who Have Never Been Screened for Colorectal Cancer, Behavioral Risk Factor Surveillance System, 2012 and 2020." *Preventing Chronic Disease* 19 (2022). ISSN: 1545-1151, accessed June 2, 2022. https://doi.org/10.5888/pcd19.220001. https://www.cdc.gov/pcd/issues/2022/22_0001.htm.

Sabatino, Susan A., Trevor D. Thompson, Mary C. White, Jean A. Shapiro, Tainya C. Clarke, Jennifer M. Croswell, and Lisa C. Richardson. "Cancer Screening Test Use8213;U.S., 2019." *American Journal of Preventive Medicine*, April 22, 2022. ISSN: 0749-3797, accessed June 2, 2022. https://doi.org/10.1016/j.amepre.2022.02.018. https://www.sciencedirect.com/science/article/pii/S0749379722001520.

Schoenborn, Nancy L., Cynthia M. Boyd, and Craig E. Pollack. "Impact of the COVID-19 pandemic on cancer screening attitudes, intentions, and behaviors in older adults." _Eprint: https://onlinelibrary.wiley.com/doi/pdf/10.111 *Journal of the American Geriatrics Society* 70, no. 1 (2022): 67–69. ISSN: 1532-5415, accessed June 2, 2022. https://doi.org/10.1111/jgs.17449. https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.17449.

Semprini, Jason. "How Did the Covid-19 Pandemic Impact Cancer Prevention and Treatment? Examining Nationally Representative Survey Data." Publisher: Wolters Kluwer, *JCO Global Oncology* 8 (Supplement_1 2022): 18–18. Accessed June 2, 2022. https://doi.org/10.1200/GO.22.24000. https://ascopubs.org/doi/abs/10.1200/GO.22.24000.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Semprini, Jason. *How did the COVID-19 Pandemic impact self-reported cancer screening rates in 12 Midwestern states?* Type: article. medRxiv, April 18, 2022. Accessed June 2, 2022. https://doi.org/10.1101/2022.04.13.22273837. https://www.medrxiv.org/content/10.1101/2022.04.13.22273837v1.

Siu, Albert L., and U.S. Preventive Services Task Force. "Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement." *Annals of Internal Medicine* 164, no. 4 (February 16, 2016): 279–296. ISSN: 1539-3704. https://doi.org/10.7326/M15-2886.

Sprague, Brian L., Ellen S. O'Meara, Christoph I. Lee, Janie M. Lee, Louise M. Henderson, Diana S. M. Buist, Nila Alsheik, et al. "Prioritizing breast imaging services during the COVID pandemic: A survey of breast imaging facilities within the Breast Cancer Surveillance Consortium." *Preventive Medicine*, From disruption to recovery: The Impact of the COVID-19 Pandemic on Cancer Screening, 151 (October 1, 2021): 106540. ISSN: 0091-7435, accessed June 2, 2022. https://doi.org/10.1016/j.ypmed.2021.106540. https://www.sciencedirect.com/science/article/pii/S0091743521001249.

Staib, James, Kierstin Catlett, and Stacey DaCosta Byfield. "Disruptions in cancer screening and diagnoses during the COVID-19 pandemic in 2020." Publisher: Wolters Kluwer, *Journal of Clinical Oncology* 39, no. 28 (October 2021): 315–315. ISSN: 0732-183X, accessed June 2, 2022. https://doi.org/10.1200/JCO.2020.39.28_suppl.315. https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.315.

Suran, Melissa. "Stagnant US Mammography Rates and the Influence of COVID-19." *JAMA* 327, no. 18 (May 10, 2022): 1742–1744. ISSN: 0098-7484, accessed June 2, 2022. https://doi.org/10.1001/jama.2022.4295. https://doi.org/10.1001/jama.2022.4295.

Velazquez, Ana I., Jessica H. Hayward, Blake Gregory, and Niharika Dixit. "Trends in Breast Cancer Screening in a Safety-Net Hospital During the COVID-19 Pandemic." *JAMA Network Open* 4, no. 8 (August 6, 2021): e2119929. ISSN: 2574-3805, accessed June 2, 2022. https://doi.org/10.1001/jamanetworkopen.2021.19929. https://doi.org/10.1001/jamanetworkopen.2021.19929.

Williams, Richard. "Using the Margins Command to Estimate and Interpret Adjusted Predictions and Marginal Effects." *The Stata Journal: Promoting communications on statistics and Stata* 12, no. 2 (June 2012): 308–331. ISSN: 1536-867X, 1536-8734, accessed June 2, 2022. https://doi.org/10.1177/1536867X1201200209. http://journals.sagepub.com/doi/10.1177/1536867X1201200209.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Files

Supplemental Figure 1: Sample Selection Flow Chart



medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Figure 2: Mammograms



Supplemental Figure 1 shows the year-by-year proportion of adults reporting having never received a mammogram, having received a mammogram in the past year, having received a mammogram 1-2 years ago, and having received a mammogram 3 or more years ago. The "early" cohort are adults surveyed by BRFSS in the first three months of the survey wave and the "late" cohort are adults surveyed in the final three months (Jan-Mar) or second year of the survey wave.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Figure 3: Pap Smears



Supplemental Figure 3 shows the year-by-year proportion of adults reporting having never received a pap smear, having received a pap smear in the past year, having received a pap smear 1-2 years ago, and having received a pap smear 3 or more years ago. The "early" cohort are adults surveyed by BRFSS in the first three months of the survey wave and the "late" cohort are adults surveyed in the final three months (Jan-Mar) or second year of the survey wave.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplemental Figure 4: Colonoscopies or Sigmoidoscopies



Supplemental Figure 3 shows the year-by-year proportion of adults reporting having never received a colonoscopy or sigmoidoscopy, having received a colonoscopy or sigmoidoscopy in the past year, having received a colonoscopy or sigmoidoscopy 1-2 years ago, and having received a colonoscopy or sigmoidoscopy 3 or more years ago. The "early" cohort are adults surveyed by BRFSS in the first three months of the survey wave and the "late" cohort are adults surveyed in the final three months (Jan-Mar) or second year of the survey wave.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Marginal Effect Estimates for 2020*Late Group (Linear & Multinomial Logistic Regression Models)

		Model	
		Linear	**Logistic**
Mammogram	Never	-0.029*	-0.028***
		(0.013)	(0.000)
	<1 Year	-0.021	-0.022
		(0.034)	(0.030)
	1-2 Years	0.031*	0.031***
		(0.015)	(0.000)
	3+ Years	0.020	0.020
		(0.024)	(0.037)
Pap Smear	Never	-0.011	-0.010
		(0.012)	(0.038)
	<1 Year	-0.043	-0.055
		(0.031)	(0.069)
	1-2 Years	0.042*	0.038*
		(0.019)	(0.027)
	3+ Years	0.012	0.028
		(0.018)	(0.019)
Colonoscopy / Sigmoidoscopy	Never	-0.010	-0.016
		(0.020)	(0.019)
	<1 Year	-0.035*	-0.043***
		(0.016)	(0.001)
	1-2 Years	0.030	0.038
		(0.016)	(0.084)
	3+ Years	0.015	0.021
		(0.019)	(0.024)

*Supplemental - Table 2 reports the 2020*Late effect estimates from our primary linear regression model (left column) and the alternative non-linear multinomail logistic regression model (right column). * $p < 0.05$, ** $p < 0.01$ *** $p < 0.001$.*

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3. Sensitivity

		Mammogram			Pap Smear			Colonoscopy / Sigmoidoscopy		
		2020*Late	**se**	**Pre-Trend Test (p)**	**2020*Late**	**se**	**Pre-Trend Test (p)**	**2020*Late**	**se**	**Pre-Trend Test (p)**
Alt. 1		-0.028	(0.014)	0.290	-0.013	(0.012)	0.000^	-0.002	(0.020)	0.009^
Alt. 2	Never	-0.028	(0.015)	0.540	-0.013	(0.012)	0.005^	-0.002	(0.027)	0.081
Alt. 3		0.005	(0.006)	0.581	-0.013	(0.012)	0.108	0.010	(0.011)	0.010^
Alt. 1		-0.030	(0.032)	0.047	-0.055	(0.031)	0.110	-0.042*	(0.016)	0.356
Alt. 2	<1 Year	-0.030	(0.028)	0.368	-0.055*	(0.025)	0.612	-0.042*	(0.020)	0.294
Alt. 3		-0.047***	(0.012)	0.083	-0.055*	(0.025)	0.008^	-0.043***	(0.009)	0.014
Alt. 1		0.036*	(0.016)	0.854	0.050*	(0.021)	0.157	0.026	(0.016)	0.207
Alt. 2	1-2 Years	0.036	(0.023)	0.935	0.050*	(0.022)	0.338	0.026	(0.019)	0.331
Alt. 3		0.031***	(0.009)	0.398	0.050*	(0.022)	0.933	0.035***	(0.009)	0.416
Alt. 1		0.022	(0.022)	0.366	0.017	(0.017)	0.011^	0.019	(0.020)	0.001^
Alt. 2	3+ Year	0.022	(0.024)	0.539	0.017	(0.025)	0.275	0.019	(0.023)	0.260
Alt. 3		0.011	(0.009)	0.618	0.017	(0.025)	0.056	-0.002	(0.009)	0.085

*Supplemental - Table 3 reports the 2020*Late effect estimates for three alternative linear probability regression models. Alt 1 removes the state-level fixed effects. Alt 2 removes the state-level fixed effects and does not cluster robust standard errors at the state-level, opting only to estimate unclustered robust standard errors. Alt 3 removes fixed effects, does not cluster robust standard errors, and does not weight the analyses by BRFSS supplied sampling weights. * p < 0.05, ** p < 0.01 *** p < 0.001.*

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 4. Self-reported rates (2010-2018) of most recent cancer screening for early and late survey groups

		Survey Wave Group					
		Eary		Late		T	p
Mammogram	Never	0.342	(0.007)	0.355	(0.009)	1.860	0.200
	<1 Year	0.400	(0.007)	0.379	(0.008)	-3.000	0.100
	1-2 Years	0.116	(0.001)	0.121	(0.003)	5.000	0.040
	3+ Years	0.143	(0.004)	0.145	(0.004)	0.500	0.670
Pap Smear	Never	0.088	(0.003)	0.102	(0.006)	4.670	0.040
	<1 Year	0.467	(0.008)	0.420	(0.009)	-5.880	0.030
	1-2 Years	0.172	(0.003)	0.186	(0.009)	4.670	0.040
	3+ Years	0.274	(0.008)	0.292	(0.008)	2.250	0.150
Colon/Sigmoidoscopy	Never	0.417	(0.006)	0.417	(0.012)	0.000	1.000
	<1 Year	0.211	(0.005)	0.195	(0.008)	-3.200	0.090
	1-2 Years	0.159	(0.004)	0.146	(0.008)	-3.250	0.080
	3+ Years	0.213	(0.006)	0.242	(0.010)	4.830	0.040

Supplemental - Table 4 reports the rates for each mutually exclusive cancer screening category (as a proportion) of the total sample of adults surveyed by BRFSS in years 2010, 2012, 2014, 2016, and 2018. The rates are stratified by adults surveyed early in the survey wave and adults surveyed later in the survey wave. The t-statistic is the result of the two-sample proportion test.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 5. Demographic rates (2010-2018) for early and late survey groups

	Survey Wave Group					
Demographic Group	**Early**		**Late**		**T**	**p**
Age 18-24	0.126	(0.002)	0.134	(0.003)	4.000	0.060
Age 25-29	0.081	(0.002)	0.091	(0.006)	5.000	0.040
Age 30-34	0.094	(0.002)	0.103	(0.003)	4.500	0.050
Age 35-39	0.081	(0.001)	0.088	(0.003)	7.000	0.020
Age 40-44	0.089	(0.001)	0.088	(0.002)	-1.000	0.420
Age 45-49	0.080	(0.001)	0.077	(0.001)	-3.000	0.100
Age 50-54	0.097	(0.001)	0.094	(0.002)	-3.000	0.100
Age 55-59	0.081	(0.001)	0.081	(0.003)	0.000	1.000
Age 60-64	0.080	(0.001)	0.077	(0.002)	-3.000	0.100
Age 65-69	0.061	(0.001)	0.059	(0.003)	-2.000	0.180
Age 70-74	0.048	(0.001)	0.043	(0.004)	-5.000	0.040
Age 75-79	0.038	(0.001)	0.030	(0.001)	-8.000	0.020
Age 80-84	0.043	(0.002)	0.034	(0.002)	-4.500	0.050
non-Hispanic White	0.659	(0.031)	0.581	(0.065)	-2.520	0.130
non-Hispanic Black	0.114	(0.011)	0.106	(0.019)	-0.730	0.540
non-Hispanic other race/ethnicity	0.074	(0.010)	0.100	(0.026)	2.600	0.120
Hispanic	0.136	(0.027)	0.197	(0.055)	2.260	0.150
No primary education	0.002	(0.001)	0.003	(0.001)	1.000	0.420
Primary education only	0.041	(0.005)	0.053	(0.011)	2.400	0.140
Some High School education, no degree	0.092	(0.002)	0.093	(0.004)	0.500	0.670
High School degree only	0.285	(0.008)	0.270	(0.015)	-1.870	0.200
Some college education, no bachelor's degree	0.305	(0.005)	0.308	(0.007)	0.600	0.610
Bachelor's degree or more	0.274	(0.007)	0.273	(0.007)	-0.140	0.900
Married	0.524	(0.005)	0.515	(0.009)	-1.800	0.210
Divorced	0.105	(0.002)	0.101	(0.004)	-2.000	0.180
Widowed	0.066	(0.002)	0.059	(0.004)	-3.500	0.070
Seperated	0.024	(0.001)	0.024	(0.001)	0.000	1.000
Never Married	0.237	(0.005)	0.251	(0.010)	2.800	0.110
Unmarried Partner	0.044	(0.002)	0.050	(0.005)	3.000	0.100

Supplemental - Table 5 reports the rates each demographic group (used as independent variables in the primary analysis) of the total sample of adults surveyed by BRFSS in years 2010, 2012, 2014, 2016, and 2018. The rates are stratified by adults surveyed early in the survey wave and adults surveyed later in the survey wave. The t-statistic is the result of the two-sample proportion test.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276836; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 6. Pre-Trend Tests

		Pre-Treatment Coefficient Estimates								
		2010*Late		2012*Late		2014*Late		2016*Late		Joint Test (p)
Mammogram	Never	-0.007	(0.018)	0.006	(0.016)	-0.013	(0.014)	-0.018	(0.012)	0.307
	<1 Year	-0.012	(0.023)	-0.022	(0.024)	0.002	(0.025)	0.021	(0.021)	0.027
	1-2 Years	-0.008	(0.021)	0.000	(0.019)	0.001	(0.020)	-0.001	(0.016)	0.965
	3+ Years	0.027	(0.021)	0.016	(0.018)	0.010	(0.013)	-0.003	(0.015)	0.499
Pap Smear	Never	0.017	(0.011)	-0.009	(0.012)	-0.025**	(0.008)	-0.010	(0.010)	0.000^
	<1 Year	0.019	(0.022)	0.018	(0.026)	0.045*	(0.021)	-0.006	(0.015)	0.007^
	1-2 Years	-0.012	(0.014)	-0.018	(0.017)	0.001	(0.017)	0.022	(0.014)	0.319
	3+ Years	-0.024	(0.016)	0.009	(0.019)	-0.021	(0.018)	-0.006	(0.017)	0.249
Colonoscopy/ Sigmoidoscopy	Never	0.019	(0.017)	0.015	(0.019)	0.019	(0.019)	-0.024	(0.018)	0.257
	<1 Year	-0.030	(0.019)	-0.023	(0.013)	-0.037	(0.023)	-0.009	(0.013)	0.445
	1-2 Years	0.012	(0.020)	-0.021	(0.015)	0.006	(0.015)	-0.009	(0.013)	0.096
	3+ Years	-0.011	(0.010)	0.014	(0.011)	-0.018*	(0.008)	-0.016	(0.009)	0.002^

*Supplemental - Table 6 reports the year-by-year coefficients of the event-history analyses (excluding 2020) with year 2018 as the baseline. Significant coefficients indicate differences in screening rate levels between quasi-treatment cohorts. The Joint Test (p) column reports the p-value from the Wald test, testing if each of the reported coeffiecient jointly equals zero. The Bonferonni correction was used to account for multiple hypotheses. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. Note: $\wedge$ $p <$ multiple-test corrected significance level for Joint Test.*